Skip to main content

Day: September 21, 2020

Power REIT Acquires Property for Greenhouse Cultivation of Cannabis in Highly Accretive Transaction

Tenant Implements State-Of-The-Art Aeroponics Growing SystemOld Bethpage, New York, Sept. 21, 2020 (GLOBE NEWSWIRE) — Power REIT (NYSE-AMEX: PW and PW.PRA) (“Power REIT” or the “Trust”) today announced that it has completed the acquisition of a 4.32 acre land parcel (“Tamarack 7”) for $150,000 located in southern Colorado through a wholly owned subsidiary (“PropCo”) which plans to construct a greenhouse for the cultivation of medical cannabis. Tamarack 7 is adjacent to several other properties that Power REIT currently owns in a Crowley County, Colorado and is approved for cannabis cultivation.Concurrent with the closing on this acquisition, PropCo entered into a “triple-net” lease that requires its tenant (“Fifth Ace”) to pay all property related expenses including maintenance, insurance and taxes. The lease has a term of 20 years...

Continue reading

Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights

AMRYT PHARMA PLC(“Amryt” or the “Company”)Exercise of Warrants & Issue of Ordinary Shares and Total Voting RightsDUBLIN, Ireland, and Boston MA, September 21 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces that an institutional investor has exercised subscription rights relating to 4,229,753 zero cost warrants (the “Warrants”).These Warrants were issued in September 2019 as part of the Company’s acquisition of Aegerion.  Certain institutional investors elected to receive Warrants to subscribe for new ordinary shares of £0.06 each (“Ordinary Shares”), in place of the same number of Ordinary Shares, as consideration for the Company’s acquisition...

Continue reading

Mercury Marine continues its growth as outboards will be offered on select Sportsman models for the first time

FOND DU LAC, Wisc., Sept. 21, 2020 (GLOBE NEWSWIRE) — Mercury Marine, a division of Brunswick Corporation (NYSE: BC), is pleased to announce that Mercury outboard engines, including the 350 and 400 Verados and other high horsepower Mercury outboards, will be offered for the first time on nine Sportsman models beginning on November 1.  Mercury has continued to grow its presence in key saltwater markets and customers from around the U.S. have been asking for higher horsepower and requesting Mercury outboards.  Sportsman, their dealers, and many other key saltwater OEM’s, are now giving their customers the opportunity to experience the power and reliability of Mercury.“We were extremely excited to hear Sportsman and Mercury are working together and we can start offering Mercury engines on Sportsman boats to our customers,” said Bill...

Continue reading

The German Sleep Society (DGSM) Recognizes PAT™ based Technology in its New Sleep-Related Breathing Disorders Guidelines, Further Benefitting Itamar Medical’s Approach to Sleep Apnea Diagnosis

CAESAREA, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the diagnosis of sleep apnea and other respiratory sleep disorders, is pleased to report that The German Sleep Society (DGSM) has released an update to its clinical guidelines for Sleep-Related Breathing Disorders (SRBD) recognizing Peripheral Arterial Tonometry (PAT™) technology as an equivalent alternative to polygraphy-based Home Sleep Apnea Testing (HSAT) systems. The new guidelines were published in Somnologie Magazine on September 9th, 2020.These guidelines set the specifications for accepted technologies and practices to be used in the diagnosis and treatment of SRBD, marking another major achievement in the recognition and adoption of PAT™ technology and PAT-based...

Continue reading

ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that clinical sites in the US and Australia are now open and ready to enrol patients into its multiple ascending dose (MAD) study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis (AD) patients. Patients will now be recruited from 4 sites in Australia, 3 sites in the US alongside 2 existing sites in Singapore.ASLAN recently restarted recruitment into the second cohort of the randomised, double blind, placebo-controlled study in Singapore following the lifting of government restrictions in response to COVID-19. All 8 patients have now been fully recruited...

Continue reading

Loncor Outlines New Mineralised Trends, In Close Proximity to Key Adumbi Deposit in the DRC

TORONTO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Loncor Resources Inc. (“Loncor” or the “Company“) (TSX: “LN”; OTCQX: “LONCF”; FSE: “LO51”) is pleased to announce that the recent exploration results have outlined a number of significant, undrilled mineralised trends at its 84.68%-owned Imbo Project. The focus of exploration by Loncor during 2020 has been along trend in the southeast of the Imbo Project from the 2.5 million ounce Adumbi, Kitenge and Manzako deposits (inferred mineral resources of 30.65 million tonnes grading 2.54 g/t Au) previously delineated in the northwest of the 122 square kilometre project area.Commenting on these results, Loncor’s President Peter Cowley said: “Situated approximately 9 kilometres from our key deposit of Adumbi, we are very encouraged by the exploration...

Continue reading

Fennec Announces Issuance of U.S. Patent for PEDMARK™

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,792,363 entitled “Anhydrous Sodium Thiosulfate and Formulations Thereof.”  As suggested by the title, the patent captures the unique anhydrous form of the active ingredient in Fennec’s PEDMARK product, as well as related methods of synthesis.  This patent is eligible for listing in the U.S Food and Drug Administration (FDA) Orange Book, and reflects Fennec’s strategy to expand and diversify its intellectual property portfolio to obtain...

Continue reading

BOTS INC TO OFFER PORTFOLIO OF CYBERSECURITY SERVICES

JACKSONVILLE, FL, Sept. 21, 2020 (GLOBE NEWSWIRE) — BOTS, Inc. (OTC: BTZI) (GERMAN EXCHANGE: M06.SG), an emerging innovator of products, technologies, and services for the rapidly growing digital robotic automation and manufacturing industry announced today that the Company is offering a portfolio of Cyber Security Services including cyber threat monitoring and analysis through Israel based operations centers, real-time monitoring, and industry-specific threat intelligence and incident response services. The Company is developing plans to set up operations centers in the U.S. BOTS Inc cybersecurity services are supported by a cloud-based platform that delivers an uninterrupted threat intelligence monitoring through a portal that will be available on the Company website.“Cybersecurity has become one of the most critical business...

Continue reading

VÍS: Samsett hlutfall og ávöxtun fjáreigna ágúst 2020

Samsett hlutfall* í ágúst 2020 var 93,1% og það sem af er ári er 108,9%. Samsett hlutfall síðustu 12 mánaða er 104,6%. Við sjáum áfram merki um lækkun á tíðni tjóna sem endurspeglast í samsettu hlutfalli í ágúst. Ávöxtun fjárfestingaeigna í ágúst var 1,1% en ávöxtun til loka ágúst frá áramótum var 6,0%. *Samsett hlutfall er tjónakostnaður, endurtryggingakostnaður og rekstrarkostnaður af vátryggingastarfsemi sem hlutfall af iðgjöldum tímabilsins samkvæmt leiðbeinandi tilmælum Seðlabanka Íslands, fjármálaeftirlits nr. 1/2020. 

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.